NCT00160225已完成2 期
A Randomized, Double-Blind, Placebo Controlled, Two-Treatment and Two-Period Cross-Over, Mono-Center Study to Evaluate the Efficacy and Safety of Daglutril 300 mg Once Daily Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •treated with optimized dose of losartan (constant dose for at least four weeks before randomization and throughout the whole study period) for at least four weeks
- •urinary albumin excretion ≥ 20 and < 1000 µg/min
- •sitting systolic/diastolic blood pressure (SBP/DBP) < 140/90 mmHg at the end of placebo run-in phase
排除标准
- •known secondary hypertension
- •decompensated congestive heart failure
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of Dulaglutide (LY2189265) in Participants With Type II DiabetesDiabetes Mellitus, Type 2NCT02152371Eli Lilly and Company300
已完成
2 期
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin MonotherapyType 2 DiabetesNCT02973100Eli Lilly and Company318
已完成
3 期
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 DiabetesType 2 Diabetes MellitusNCT04591626Eli Lilly and Company291
已完成
3 期
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.Acute Myocardial InfarctionHeart FailureNCT04564742AstraZeneca4,017
已完成
3 期
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02597049Eli Lilly and Company424